PIŚMIENNICTWO
1. Vail DM et al. Hematopoietic tumors, section a: canine lymphoma and lymphocytic leukemias. InVail DM, Thamm D, Liptak J. Saunders, eds. Withrow and MacEwen’s Small Animal Clinical Oncology. 6th ed. Elsevier;2019:688-712.
2. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2002;16(6):704-709. doi:10.1892/0891-6640(2002)016<0704:eoacpw>2.3.co;2
3. Regan RC, Kaplan MS, Bailey DB. Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians. Vet Comp Oncol. 2013;11(4):287-295. doi:10.1111/j.1476-5829.2012.00318.x
4. Weishaar KM, Wright ZM, Rosenberg MP, et al. Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma. J Vet Intern Med. 2022;36(1):215-226. doi:10.1111/jvim.16341
5. Saba CF, Clifford C, Burgess K, et al. Rabacfosadine for naive canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Vet Comp Oncol. 2020;18(4):763-769. doi:10.1111/vco.12605
6. Saba CF, Vickery KR, Clifford CA, et al. Rabacfosadine for relapsed canine B-cell lymphoma: efficacy and adverse event profiles of 2 different doses. Vet Comp Oncol. 2018;16(1):E76-E82. doi:10.1111/vco.12337
7. Thamm DH, Vail DM, Post GS, et al. Alternating rabacfosadine/doxorubicin: efficacy and tolerability in naive canine multicentric lymphoma. J Vet Intern Med. 2017;31(3):872-878. doi:10.1111/jvim.14700
8. London CA, Bernabe LF, Barnard S, et al. Preclinical evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS One. 2014;9(2):e87585. doi:10.1371/journal.pone.0087585
9. Laverdia-CA1 Package Insert, Anivive Lifesciences, 2020.
10. Bergman, PJ, Clifford CA, Thamm D, Johannes C. Clinical integration of Tanovea® and Laverdia™-ca1 for canine lymphoma. Presented at: 2022 ACVIM Forum; June 23-25; Austin TX.
11. Sadowski AR, Gardner HL, Borgatti A, et al. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res. 2018;14(1):250. doi:10.1186/s12917-018-1587-9
